Pioglitazone Intervention for Coronary Atherosclerosis in Patients with Metabolic Syndrome.
Phase 2
- Conditions
- Coronary atherosclerosis Metabolic syndrome
- Registration Number
- JPRN-C000000332
- Lead Sponsor
- Department of Cardiovascular Medicine Saitama Medical University International Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Acute coronary syndrome (acute myocardial infarction / unstable angina) Undergo insulin therapy Severe liver dysfunction, severe renal dysfunction Undergo treatment of heart failure Already taking pioglitazone History of side effect of thiazolidines CD36 defficiency Pregnancy or possible pregnancy Non-hypertension
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in volume of coronary atherosclerotic plaque evaluated by intravascular ultrasound Change in tissue components of coronary atherosclerotic plaque evaluated by intravascular ultrasound Change in plasma lipid profile Change in inflammatory markers
- Secondary Outcome Measures
Name Time Method Death, Acute coronary syndrome, Newly onset of angina whose culprit lesion is subjective plaque, Severe heart failure